Erlotinib Hydrochloride – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 82 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Erlotinib Hydrochloride - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer. Erlotinib therapy is associated with transient elevations in serum aminotransferase levels during therapy and rare instances of clinically apparent acute liver injury. Erlotinib...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer. Erlotinib therapy is associated with transient elevations in serum aminotransferase levels during therapy and rare instances of clinically apparent acute liver injury. Erlotinib is a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer. Erlotinib therapy is associated with transient elevations in serum aminotransferase levels during therapy and rare instances of clinically apparent acute liver injury.

Erlotinib is a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.

Erlotinib is a quinazoline compound having a (3-ethynyl phenyl)amino group at the 4-position and two 2-methoxy ethoxy groups at the 6- and 7-positions. It has a role as an antineoplastic agent, a protein kinase inhibitor, and an epidermal growth factor receptor antagonist. It is a member of quinazolines, a terminal acetylenic compound, an aromatic ether, and a secondary amino compound.

Erlotinib Hydrochloride is the hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer, and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders

Mechanism of Action

The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). The specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.

Although the exact mechanism of antineoplastic activity of erlotinib has not been fully elucidated, erlotinib appears to inhibit the intracellular phosphorylation of tyrosine kinase associated with EGFR, which is expressed on the surface of normal and cancer cells. Specificity with regard to other tyrosine kinase receptors has not been fully characterized.

or

Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong survival after the failure of first-line or second-line chemotherapy. However, little is known about its effects on the immune system. In the present study, /investigators/ aimed to investigate the immunosuppressive activity of erlotinib on T lymphocytes both in vitro and in vivo, and further explore its potential molecular mechanism. Erlotinib exerted a significant inhibition on the T cell proliferation and activation induced by concanavalin A, anti-CD3 plus anti-CD28, staphylococcal enterotoxin B or phorbol myristate acetate respectively in a concentration-dependent manner and also inhibited the secretion of the proinflammatory cytokines such as IL-2 and IFN-gamma of activated T cells. Further study showed that erlotinib caused G0/G1 arrest and suppressed the phosphorylations of c-Raf, ERK, and Akt in activated T cells. Moreover, erlotinib significantly ameliorated picryl chloride-induced ear contact dermatitis in a dose-dependent manner in vivo. In summary, these findings suggest that erlotinib may cause the impairment of T-cell-mediated immune response both in vitro and in vivo through inhibiting T-cell proliferation and activation, which is closely associated with its potent down-regulation of the c-Raf/ERK cascade and Akt signaling pathway.

Indications

  • Erlotinib is indicated for: – The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. – In combination with the first-line treatment for patients diagnosed with locally advanced, unresectable, or metastatic pancreatic cancer. The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally, it is not recommended for use in combination with platinum-based chemotherapy.
  • Non-small cell lung cancer (NSCLC): Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In patients with tumors without EGFR-activating mutations, Tarceva is indicated when other treatment options are not considered suitable. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth
  • Pancreatic cancer: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer.
  • Non-small cell lung cancer (NSCLC): Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In patients with tumors without EGFR-activating mutations, Tarceva is indicated when other treatment options are not considered suitable. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC – negative tumors.
  • Pancreatic cancer: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. Erlotinib hydrochloride in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.
  • Locally Advanced Pancreatic Cancer (LAPC)
  • Metastatic Non-Small Cell Lung Cancer
  • Pancreatic Metastatic Cancer
  • Unresectable Pancreatic Cancer

Use in Cancer

Erlotinib hydrochloride is approved to be used alone or with other drugs to treat:

  • Non-small cell lung cancer (NSCLC) is metastatic and has certain EGFR gene mutations. It may be used:
    • As the first therapy.
    • In patients on maintenance therapy or whose disease has gotten worse after treatment with chemotherapy.

    The use of erlotinib hydrochloride to treat NSCLC that does not have the EGFR gene mutations is no longer FDA-approved.

  • Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose cancer cannot be removed by surgery or has spread.

Erlotinib hydrochloride is also being studied in the treatment of other types of cancer.

Contraindications

  • Interstitial lung disease (ILD) Severe hepatic toxicity that is unimproved or does not resolve.
  • GI perforation.
  • Severe bullous, blistering, or exfoliating skin conditions.
  • Corneal perforation or severe ulceration.
  • liver cancer
  • dehydration
  • low amount of potassium in the blood
  • a type of blood disorder where the red blood cells burst called hemolytic anemia
  • increased risk of bleeding due to clotting disorder
  • decreased blood platelets
  • an ulcer of the cornea of the eye
  • a heart attack
  • a low supply of oxygen-rich blood to the heart
  • thrombotic thrombocytopenic purpura, a type of blood disorder
  • bleeding
  • a type of infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of the lung called interstitial pneumonitis
  • a condition where there is a formation of fibrous tissue in the lung called pulmonary chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।" data-rx-term="fibrosis" data-rx-definition="Fibrosis means excess scar-like tissue formation after chronic injury or inflammation. সহজ বাংলা: অতিরিক্ত দাগের মতো টিস্যু তৈরি হওয়া।">fibrosis
  • acute respiratory distress syndrome, a type of lung disorder
  • liver problems
  • acute renal failure in patients with serious liver disease
  • the high amount of jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin in the blood
  • abnormal liver function tests
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • a rupture in the wall of the stomach or intestine
  • tobacco smoking
  • lung tissue problem
  • kidney disease with likely reduction in kidney function

Dosage

Strengths: 25 mg; 100 mg; 150 mg

Non-Small Cell Lung Cancer

  • 150 mg orally once a day on an empty stomach (at least 1 hour before or 2 hours after food)
  • Duration of therapy: Until disease progression or unacceptable toxicity

Pancreatic Cancer

  • 100 mg orally once a day on an empty stomach (at least 1 hour before or 2 hours after food)
  • Duration of therapy: Until disease progression or unacceptable toxicity

Therapy should be interrupted or discontinued if:

  • Total serum jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin doubles and/or serum transaminases triple in patients with baseline hepatic impairment
  • Total serum jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin is greater than 3 times the upper limit of normal (3 x ULN) and/or serum transaminases are greater than 5 x ULN in patients with normal pretreatment values.

Dose Adjustments

Discontinue therapy for:

  • Interstitial Lung Disease (ILD)
  • Severe hepatic toxicity that does not improve significantly or resolve within 3 weeks
  • GI perforation
  • Severe bullous, blistering, or exfoliating skin conditions
  • Corneal perforation or severe ulceration

Interrupt therapy:

  • During diagnostic evaluation for ILD
  • In patients with preexisting hepatic impairment or biliary obstruction for doubling of jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin or tripling of transaminases values over baseline; consider discontinuing therapy
  • In patients without preexisting hepatic impairment for total jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।" data-rx-term="bilirubin" data-rx-definition="Bilirubin is a yellow pigment that can build up in jaundice. সহজ বাংলা: জন্ডিসে বাড়তে পারে এমন হলুদ রঞ্জক।">bilirubin levels greater than 3 x ULN or transaminases greater than 5 x ULN; consider discontinuing therapy
  • For severe (CTCAE grade 3 to 4) renal toxicity; consider discontinuing therapy
  • For persistent severe diarrhea not responsive to medical management (e.g., loperamide)
  • For severe rash not responsive to medical management
  • For Grade 3 or 4 keratitis or Grade 2 keratitis lasting more than 2 weeks
  • For acute/worsening ocular disorders such as eye pain; consider discontinuing therapy
  • If severe reactions occur with concomitant use of strong CYP450 3A4 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole), or grapefruit or grapefruit juice, or when used concomitantly with an inhibitor of both CYP450 3A4 and CYP450 1A2 (e.g., ciprofloxacin): Reduce dose by 50 mg decrements and avoid concomitant use if possible
  • Concomitant use with CYP450 3A4 inducers (e.g., rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, St. John’s Wort: Increase dose by 50 mg increments every 2 weeks to a maximum dose of 450 mg as tolerated; avoid concomitant use if possible
  • Concurrent cigarette smoking: Increase the dose by 50 mg every 2 weeks to a maximum dose of 300 mg. Upon cessation of smoking, immediately reduce the dose to the recommended dose (150 mg or 100 mg daily)
  • Proton pump inhibitors: Avoid concomitant use if possible; separation of doses may not eliminate the interaction since proton pump inhibitors affect the pH of the upper GI tract for an extended period
  • H2-receptor antagonists: Erlotinib must be taken 10 hours after the H2-receptor antagonist and at least 2 hours before the next dose of the H2-receptor antagonist
  • Antacids: The antacid dose and the dose of erlotinib should be separated by several hours if an antacid is necessary; the effect of antacids on erlotinib pharmacokinetics has not been evaluated

Administration advice:

  • Take this drug at least 1 hour before or 2 hours after food.
  • Avoid taking this drug with antacids, histamine-2 antagonists, and proton pump inhibitors.

Side  Effects

The Most Common

  • diarrhea
  • loss of appetite
  • nausea
  • vomiting
  • heartburn
  • gas
  • constipation
  • mouth sores
  • weight loss
  • extreme tiredness
  • headache
  • bone or muscle pain
  • depression
  • anxiety
  • numbness, burning, or tingling of the hands or feet
  • swelling of the arms, hands, feet, ankles, or lower legs
  • darkening of skin
  • hair loss
  • changes in the appearance of the hair and nails
  • rash (may look like acne and may affect the skin on the face, upper chest, or back)
  • blistering, peeling, dry, or cracked skin
  • itching, tenderness, or burning of the skin
  • shortness of breath
  • cough
  • fever or chills
  • growth of eyelashes on the inside of the eyelid
  • severe stomach pain
  • dry, red, painful, teary, or irritated eyes
  • blurred vision
  • eye sensitivity to light
  • chest pain or pressure
  • pain in the arms, neck, or upper back
  • rapid, irregular, or pounding heartbeat
  • slow or difficult speech
  • dizziness or faintness
  • weakness or numbness of an arm or leg
  • unusual bruising or bleeding
  • black and tarry or bloody stools
  • vomit that is bloody or looks like coffee grounds
  • sunken eyes
  • dry mouth
  • decreased urination
  • dark urine
  • pale or yellow skin
  • redness, warmth, pain, tenderness, or swelling in one leg

More common

  • Burning, tingling, numbness or pain in the hands, arms, feet, or legs
  • cough or hoarseness
  • diarrhea (severe)
  • difficult or labored breathing
  • fever or chills
  • lower back or side pain
  • painful or difficult urination
  • rash (severe)
  • sensation of pins and needles
  • stabbing chest pain
  • tightness in the chest
  • Acid or sour stomach
  • belching
  • blemishes on the skin
  • bloated or full feeling
  • bone pain
  • burning, dry, or itching eyes
  • diarrhea (mild)
  • difficulty with moving
  • dizziness
  • dry eyes
  • dry skin
  • excess air or gas in the stomach or intestines
  • excessive tearing

Rare

  • Bloody or black, tarry stools
  • blurred vision
  • chest pain or discomfort
  • constipation
  • convulsions (seizures)
  • eye irritation or redness
  • inability to speak
  • pain or discomfort in the arms, jaw, back, or neck
  • severe stomach pain
  • slurred speech
  • sudden, severe chest pain
  • sudden, severe headache
  • sudden, severe weakness in the arm or leg on one side of the body
  • sweating
  • vision changes
  • vomiting of blood or material that looks like coffee grounds
  • Agitation
  • blistering, peeling, or loosening of the skin
  • bloody nose
  • burning feeling in the chest or stomach
  • burning upper abdominal or stomach pain
  • confusion
  • dark-colored urine
  • darkening of the skin
  • decreased urine output
  • general feeling of tiredness or weakness
  • headache
  • increased thirst
  • irregular heartbeat
  • lethargy
  • light-colored stools
  • loss of appetite
  • mood changes
  • muscle pain or stiffness
  • muscle twitching
  • nausea or vomiting
  • rapid weight gain
  • red skin lesions, often with a purple center
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • stomach pain, continuing
  • stupor
  • swelling of the face, ankles, or hands
  • tenderness in the stomach area
  • trouble breathing
  • unusual tiredness or weakness
  • yellow eyes or skin

Drug Interaction

Pregnancy and Lactation

FDA Pregnancy Category D 

Pregnancy

Erlotinib can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised not to become pregnant while being treated with erlotinib. Erlotinib has been shown to cause maternal toxicity with associated embryofetal lethality and abortion in rabbits when given at doses that result in plasma drug concentrations of approximately 3 times those in humans (AUCs at 150 mg daily dose). When given during the period of organogenesis to achieve plasma drug concentrations approximately equal to those in humans, based on AUC, there was no increased incidence of embryofetal lethality or abortion in rabbits or rats.

Lactation

No information is available on the clinical use of erlotinib during breastfeeding. Because erlotinib is 93% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 36 hours and it might accumulate in the infant. It is also given in combination with gemcitabine for pancreatic cancer, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during erlotinib therapy and for 2 weeks after the final dose.

How should this medicine be used?

Erlotinib comes as a tablet to take by mouth. It is usually taken on an empty stomach once a day, at least 1 hour before or 2 hours after eating a meal or snack. Take erlotinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take erlotinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor may decrease your dose of erlotinib during your treatment. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take erlotinib even if you feel well. Do not stop taking erlotinib without talking to your doctor.

What special precautions should I follow?

Before taking erlotinib,

  • tell your doctor and pharmacist if you are allergic to erlotinib, any other medications, or any of the ingredients in erlotinib tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: angiogenesis inhibitors such as bevacizumab (Avastin); anticoagulants (‘blood thinners’) such as warfarin (Coumadin); certain antifungals such as itraconazole (Sporanox), ketoconazole (Nizoral), posaconazole (Noxafil), and voriconazole (Vfend); boceprevir (Victrelis); carbamazepine (Tegretol); ciprofloxacin (Cipro, Proquin XR); clarithromycin (Biaxin); conivaptan (Vaprisol); HIV protease inhibitors such as atazanavir (Reyataz), indinavir (Crixivan), lopinavir/ritonavir (Kaletra), nelfinavir (Viracept), ritonavir (Norvir), and saquinavir (Fortovase, Invirase); H2 blockers such as cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), and ranitidine (Zantac); medications for acne such as benzoyl peroxide (in Epiduo, in BenzaClin, in Benzamycin, others); midazolam (Versed): nefazodone; nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin) and naproxen (Aleve, Naprosyn); oral steroids such as dexamethasone (Decadron, Dexone), methylprednisolone (Medrol), and prednisone (Deltasone); phenobarbital (Luminal, Solfoton); phenytoin (Dilantin); proton pump inhibitors such as esomeprazole (Nexium), lansoprazole (Prevacid), omeprazole (Prilosec), pantoprazole (Protonix), and rabeprazole (AcipHex); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane); rifapentine; taxane medications for cancer such as docetaxel (Taxotere) and paclitaxel (Abraxane, Taxol); telithromycin (Ketek); teriflunomide (Aubagio); and troleandomycin (TAO) (not available in the U.S.). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with erlotinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • if you are taking antacids, take them several hours before or several hours after you take erlotinib.
  • tell your doctor what herbal products you are taking, especially St. John’s wort.
  • tell your doctor if you are being treated or have recently been treated with chemotherapy or radiation therapy (treatment for cancer that uses waves of high-energy particles to kill cancer cells). Also tell your doctor if you have or have ever had lung disease or infection, stomach ulcers, diverticular disease (a condition in which abnormal pouches form in the large intestine and may become inflamed), or liver or kidney disease.
  • tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while you are taking erlotinib and for at least 1 month after your final dose. Talk to your doctor about birth control methods that you can use. If you become pregnant, call your doctor immediately. Erlotinib may harm the fetus.
  • tell your doctor if you are breastfeeding. You should not breastfeed during your treatment with erlotinib and for up to 2 weeks after your final dose.
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking erlotinib.
  • tell your doctor if you use tobacco products. Cigarette smoking may decrease the effectiveness of this medication.
  • plan to avoid unnecessary or prolonged exposure to sunlight and to wear a hat, other protective clothing, sunglasses, and sunscreen. Choose a sunscreen that has a sun protection factor (SPF) of at least 15 and contains zinc oxide or titanium dioxide. Exposure to sunlight increases the risk that you will develop a rash during your treatment with erlotinib.
  • you should know that erlotinib may cause rashes and other skin problems. To protect your skin, use a mild alcohol-free moisturizer, wash your skin with mild soap, and remove cosmetics with a mild cleanser.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Erlotinib Hydrochloride – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). The specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells. Although the exact mechanism of antineoplastic activity of erlotinib has not been fully elucidated, erlotinib appears to inhibit the intracellular phosphorylation of tyrosine kinase associated with EGFR, which is expressed on the surface of normal and cancer cells. Specificity with regard to other tyrosine kinase receptors has not been fully characterized. or Erlotinib is a potent inhibitor of epidermal growth factor receptor tyrosine kinase and has been demonstrated to treat advanced or metastatic non-small cell lung cancer to prolong survival after the failure of first-line or second-line chemotherapy. However, little is known about its effects on the immune system. In the present study, /investigators/ aimed to investigate the immunosuppressive activity of erlotinib on T lymphocytes both in vitro and in vivo, and further explore its potential molecular mechanism. Erlotinib exerted a significant inhibition on the T cell proliferation and activation induced by concanavalin A, anti-CD3 plus anti-CD28, staphylococcal enterotoxin B or phorbol myristate acetate respectively in a concentration-dependent manner and also inhibited the secretion of the proinflammatory cytokines such as IL-2 and IFN-gamma of activated T cells. Further study showed that erlotinib caused G0/G1 arrest and suppressed the phosphorylations of c-Raf, ERK, and Akt in activated T cells. Moreover, erlotinib significantly ameliorated picryl chloride-induced ear contact dermatitis in a dose-dependent manner in vivo. In summary, these findings suggest that erlotinib may cause the impairment of T-cell-mediated immune response both in vitro and in vivo through inhibiting T-cell proliferation and activation, which is closely associated with its potent down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Indications Erlotinib is indicated for: - The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. - In combination with the first-line treatment for patients diagnosed with locally advanced, unresectable, or metastatic pancreatic cancer. The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally, it is not recommended for use in combination with platinum-based chemotherapy. Non-small cell lung cancer (NSCLC): Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In patients with tumors without EGFR-activating mutations, Tarceva is indicated when other treatment options are not considered suitable. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Pancreatic cancer: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer. Non-small cell lung cancer (NSCLC): Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. In patients with tumors without EGFR-activating mutations, Tarceva is indicated when other treatment options are not considered suitable. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumors. Pancreatic cancer: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer. When prescribing Tarceva, factors associated with prolonged survival should be taken into account. Erlotinib hydrochloride in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer. Locally Advanced Pancreatic Cancer (LAPC) Metastatic Non-Small Cell Lung Cancer Pancreatic Metastatic Cancer Unresectable Pancreatic Cancer Use in Cancer Erlotinib hydrochloride is approved to be used alone or with other drugs to treat: Non-small cell lung cancer (NSCLC) is metastatic and has certain EGFR gene mutations. It may be used: As the first therapy. In patients on maintenance therapy or whose disease has gotten worse after treatment with chemotherapy. The use of erlotinib hydrochloride to treat NSCLC that does not have the EGFR gene mutations is no longer FDA-approved. Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose cancer cannot be removed by surgery or has spread. Erlotinib hydrochloride is also being studied in the treatment of other types of cancer. Contraindications Interstitial lung disease (ILD) Severe hepatic toxicity that is unimproved or does not resolve. GI perforation. Severe bullous, blistering, or exfoliating skin conditions. Corneal perforation or severe ulceration. liver cancer dehydration low amount of potassium in the blood a type of blood disorder where the red blood cells burst called hemolytic anemia increased risk of bleeding due to clotting disorder decreased blood platelets an ulcer of the cornea of the eye a heart attack a low supply of oxygen-rich blood to the heart thrombotic thrombocytopenic purpura, a type of blood disorder bleeding a type of inflammation of the lung called interstitial pneumonitis a condition where there is a formation of fibrous tissue in the lung called pulmonary fibrosis acute respiratory distress syndrome, a type of lung disorder liver problems acute renal failure in patients with serious liver disease the high amount of bilirubin in the blood abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding a rupture in the wall of the stomach or intestine tobacco smoking lung tissue problem kidney disease with likely reduction in kidney function Dosage Strengths: 25 mg; 100 mg; 150 mg Non-Small Cell Lung Cancer 150 mg orally once a day on an empty stomach (at least 1 hour before or 2 hours after food) Duration of therapy: Until disease progression or unacceptable toxicity Pancreatic Cancer 100 mg orally once a day on an empty stomach (at least 1 hour before or 2 hours after food) Duration of therapy: Until disease progression or unacceptable toxicity Therapy should be interrupted or discontinued if: Total serum bilirubin doubles and/or serum transaminases triple in patients with baseline hepatic impairment Total serum bilirubin is greater than 3 times the upper limit of normal (3 x ULN) and/or serum transaminases are greater than 5 x ULN in patients with normal pretreatment values. Dose Adjustments Discontinue therapy for: Interstitial Lung Disease (ILD) Severe hepatic toxicity that does not improve significantly or resolve within 3 weeks GI perforation Severe bullous, blistering, or exfoliating skin conditions Corneal perforation or severe ulceration Interrupt therapy: During diagnostic evaluation for ILD In patients with preexisting hepatic impairment or biliary obstruction for doubling of bilirubin or tripling of transaminases values over baseline; consider discontinuing therapy In patients without preexisting hepatic impairment for total bilirubin levels greater than 3 x ULN or transaminases greater than 5 x ULN; consider discontinuing therapy For severe (CTCAE grade 3 to 4) renal toxicity; consider discontinuing therapy For persistent severe diarrhea not responsive to medical management (e.g., loperamide) For severe rash not responsive to medical management For Grade 3 or 4 keratitis or Grade 2 keratitis lasting more than 2 weeks For acute/worsening ocular disorders such as eye pain; consider discontinuing therapy If severe reactions occur with concomitant use of strong CYP450 3A4 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole), or grapefruit or grapefruit juice, or when used concomitantly with an inhibitor of both CYP450 3A4 and CYP450 1A2 (e.g., ciprofloxacin): Reduce dose by 50 mg decrements and avoid concomitant use if possible Concomitant use with CYP450 3A4 inducers (e.g., rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, St. John's Wort: Increase dose by 50 mg increments every 2 weeks to a maximum dose of 450 mg as tolerated; avoid concomitant use if possible Concurrent cigarette smoking: Increase the dose by 50 mg every 2 weeks to a maximum dose of 300 mg. Upon cessation of smoking, immediately reduce the dose to the recommended dose (150 mg or 100 mg daily) Proton pump inhibitors: Avoid concomitant use if possible; separation of doses may not eliminate the interaction since proton pump inhibitors affect the pH of the upper GI tract for an extended period H2-receptor antagonists: Erlotinib must be taken 10 hours after the H2-receptor antagonist and at least 2 hours before the next dose of the H2-receptor antagonist Antacids: The antacid dose and the dose of erlotinib should be separated by several hours if an antacid is necessary; the effect of antacids on erlotinib pharmacokinetics has not been evaluated Administration advice: Take this drug at least 1 hour before or 2 hours after food. Avoid taking this drug with antacids, histamine-2 antagonists, and proton pump inhibitors. Side  Effects The Most Common diarrhea loss of appetite nausea vomiting heartburn gas constipation mouth sores weight loss extreme tiredness headache bone or muscle pain depression anxiety numbness, burning, or tingling of the hands or feet swelling of the arms, hands, feet, ankles, or lower legs darkening of skin hair loss changes in the appearance of the hair and nails rash (may look like acne and may affect the skin on the face, upper chest, or back) blistering, peeling, dry, or cracked skin itching, tenderness, or burning of the skin shortness of breath cough fever or chills growth of eyelashes on the inside of the eyelid severe stomach pain dry, red, painful, teary, or irritated eyes blurred vision eye sensitivity to light chest pain or pressure pain in the arms, neck, or upper back rapid, irregular, or pounding heartbeat slow or difficult speech dizziness or faintness weakness or numbness of an arm or leg unusual bruising or bleeding black and tarry or bloody stools vomit that is bloody or looks like coffee grounds sunken eyes dry mouth decreased urination dark urine pale or yellow skin redness, warmth, pain, tenderness, or swelling in one leg More common Burning, tingling, numbness or pain in the hands, arms, feet, or legs cough or hoarseness diarrhea (severe) difficult or labored breathing fever or chills lower back or side pain painful or difficult urination rash (severe) sensation of pins and needles stabbing chest pain tightness in the chest Acid or sour stomach belching blemishes on the skin bloated or full feeling bone pain burning, dry, or itching eyes diarrhea (mild) difficulty with moving dizziness dry eyes dry skin excess air or gas in the stomach or intestines excessive tearing Rare Bloody or black, tarry stools blurred vision chest pain or discomfort constipation convulsions (seizures) eye irritation or redness inability to speak pain or discomfort in the arms, jaw, back, or neck severe stomach pain slurred speech sudden, severe chest pain sudden, severe headache sudden, severe weakness in the arm or leg on one side of the body sweating vision changes vomiting of blood or material that looks like coffee grounds Agitation blistering, peeling, or loosening of the skin bloody nose burning feeling in the chest or stomach burning upper abdominal or stomach pain confusion dark-colored urine darkening of the skin decreased urine output general feeling of tiredness or weakness headache increased thirst irregular heartbeat lethargy light-colored stools loss of appetite mood changes muscle pain or stiffness muscle twitching nausea or vomiting rapid weight gain red skin lesions, often with a purple center sore throat sores, ulcers, or white spots in the mouth or on the lips stomach pain, continuing stupor swelling of the face, ankles, or hands tenderness in the stomach area trouble breathing unusual tiredness or weakness yellow eyes or skin Drug Interaction DRUG INTERACTION Abacavir The metabolism of Abacavir can be decreased when combined with Erlotinib. Abaloparatide The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Erlotinib. Abametapir The serum concentration of Erlotinib can be increased when it is combined with Abametapir. Abatacept The metabolism of Erlotinib can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Erlotinib. Abiraterone The serum concentration of Erlotinib can be increased when it is combined with Abiraterone. Acalabrutinib The metabolism of Erlotinib can be decreased when combined with Acalabrutinib. Acebutolol The metabolism of Erlotinib can be decreased when combined with Acebutolol. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Erlotinib. Acetaminophen The serum concentration of Erlotinib can be decreased when it is combined with Acetaminophen. Acetazolamide The metabolism of Erlotinib can be decreased when combined with Acetazolamide. Acrivastine The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Erlotinib. Acyclovir The metabolism of Acyclovir can be decreased when combined with Erlotinib. Adalimumab The metabolism of Erlotinib can be increased when combined with Adalimumab. Adenosine The risk or severity of QTc prolongation can be increased when Adenosine is combined with Erlotinib. Afatinib Erlotinib may decrease the excretion rate of Afatinib which could result in a higher serum level. Agomelatine The metabolism of Agomelatine can be decreased when combined with Erlotinib. Ajmaline The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Erlotinib. Albendazole The metabolism of Erlotinib can be increased when combined with Albendazole. Aldesleukin The metabolism of Erlotinib can be decreased when combined with Aldesleukin. Alectinib The metabolism of Alectinib can be decreased when combined with Erlotinib. Alfentanil The metabolism of Erlotinib can be decreased when combined with Alfentanil. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Erlotinib. Alimemazine The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Erlotinib. Allopurinol Erlotinib may decrease the excretion rate of Allopurinol which could result in a higher serum level. Almasilate Almasilate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Almotriptan The metabolism of Erlotinib can be decreased when combined with Almotriptan. Alogliptin The metabolism of Erlotinib can be decreased when combined with Alogliptin. Alosetron The metabolism of Erlotinib can be decreased when combined with Alosetron. Alpelisib The serum concentration of Erlotinib can be decreased when it is combined with Alpelisib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Erlotinib. Aluminium Aluminium phosphate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Erlotinib. Ambrisentan The metabolism of Erlotinib can be decreased when combined with Ambrisentan. Amifampridine The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Erlotinib. Aminoglutethimide The serum concentration of Erlotinib can be decreased when it is combined with Aminoglutethimide. Aminophenazone The metabolism of Erlotinib can be decreased when combined with Aminophenazone. Aminophylline The metabolism of Aminophylline can be decreased when combined with Erlotinib. Amiodarone The metabolism of Erlotinib can be decreased when combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Erlotinib. Amitriptyline The metabolism of Erlotinib can be decreased when combined with Amitriptyline. Amobarbital The serum concentration of Erlotinib can be decreased when it is combined with Amobarbital. Amodiaquine The metabolism of Erlotinib can be decreased when combined with Amodiaquine. Amoxapine The metabolism of Erlotinib can be decreased when combined with Amoxapine. Amphetamine The metabolism of Erlotinib can be decreased when combined with Amphetamine. Amprenavir The metabolism of Erlotinib can be decreased when combined with Amprenavir. Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Erlotinib. Anakinra The metabolism of Erlotinib can be increased when combined with Anakinra. Anastrozole The metabolism of Erlotinib can be decreased when combined with Anastrozole. Antazoline The risk or severity of QTc prolongation can be increased when Antazoline is combined with Erlotinib. Antipyrine The metabolism of Erlotinib can be decreased when combined with Antipyrine. Apalutamide The metabolism of Erlotinib can be increased when combined with Apalutamide. Apixaban The metabolism of Erlotinib can be decreased when combined with Apixaban. Apomorphine The metabolism of Erlotinib can be decreased when combined with Apomorphine. Apremilast The metabolism of Erlotinib can be increased when combined with Apremilast. Aprepitant The metabolism of Erlotinib can be decreased when combined with Aprepitant. Arformoterol The metabolism of Erlotinib can be decreased when combined with Arformoterol. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Erlotinib. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Erlotinib. Armodafinil The serum concentration of Erlotinib can be decreased when it is combined with Armodafinil. Arsenic trioxide The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Arsenic trioxide. Artemether The serum concentration of Erlotinib can be decreased when it is combined with Artemether. Artenimol The metabolism of Erlotinib can be decreased when combined with Artenimol. Articaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Articaine. Asciminib The serum concentration of Erlotinib can be increased when it is combined with Asciminib. Asenapine Asenapine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Astemizole The metabolism of Astemizole can be decreased when combined with Erlotinib. Asunaprevir The serum concentration of Erlotinib can be decreased when it is combined with Asunaprevir. Atazanavir The metabolism of Erlotinib can be decreased when combined with Atazanavir. Atenolol The metabolism of Erlotinib can be decreased when combined with Atenolol. Atomoxetine The metabolism of Erlotinib can be decreased when combined with Atomoxetine. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Erlotinib. Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Erlotinib. Avacopan The metabolism of Erlotinib can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Erlotinib. Avatrombopag The metabolism of Erlotinib can be increased when combined with Avatrombopag. Axitinib The metabolism of Axitinib can be decreased when combined with Erlotinib. Azatadine The risk or severity of QTc prolongation can be increased when Azatadine is combined with Erlotinib. Azathioprine The metabolism of Azathioprine can be decreased when combined with Erlotinib. Azelastine The metabolism of Erlotinib can be decreased when combined with Azelastine. Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Erlotinib. Bazedoxifene The metabolism of Bazedoxifene can be decreased when combined with Erlotinib. Beclomethasone The serum concentration of Erlotinib can be decreased when it is combined with Beclomethasone dipropionate. Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Erlotinib. Belinostat The metabolism of Belinostat can be decreased when combined with Erlotinib. Belzutifan The serum concentration of Erlotinib can be decreased when it is combined with Belzutifan. Bendamustine The metabolism of Bendamustine can be decreased when combined with Erlotinib. Benzatropine The metabolism of Erlotinib can be decreased when combined with Benzatropine. Benzocaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Benzyl alcohol. Bepridil The metabolism of Erlotinib can be decreased when combined with Bepridil. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Erlotinib. Betamethasone The serum concentration of Erlotinib can be decreased when it is combined with Betamethasone. Betamethasone The metabolism of Erlotinib can be increased when combined with Betamethasone phosphate. Betaxolol The metabolism of Erlotinib can be decreased when combined with Betaxolol. Bexarotene The serum concentration of Erlotinib can be decreased when it is combined with Bexarotene. Bezafibrate The metabolism of Erlotinib can be decreased when combined with Bezafibrate. Bicalutamide The metabolism of Erlotinib can be decreased when combined with Bicalutamide. Bictegravir The metabolism of Bictegravir can be decreased when combined with Erlotinib. Bifonazole The metabolism of Erlotinib can be decreased when combined with Bifonazole. Bilastine The risk or severity of QTc prolongation can be increased when Bilastine is combined with Erlotinib. Bimekizumab The metabolism of Erlotinib can be increased when combined with Bimekizumab. Binimetinib The metabolism of Binimetinib can be decreased when combined with Erlotinib. Biperiden The metabolism of Erlotinib can be decreased when combined with Biperiden. Bismuth subnitrate Bismuth subnitrate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Boceprevir The metabolism of Erlotinib can be decreased when combined with Boceprevir. Bortezomib The metabolism of Bortezomib can be decreased when combined with Erlotinib. Bosentan The serum concentration of Erlotinib can be decreased when it is combined with Bosentan. Bosutinib The metabolism of Bosutinib can be decreased when combined with Erlotinib. Brentuximab The metabolism of Brentuximab vedotin can be decreased when combined with Erlotinib. Bretylium The risk or severity of QTc prolongation can be increased when Bretylium is combined with Erlotinib. Brexpiprazole The metabolism of Erlotinib can be decreased when combined with Brexpiprazole. Brigatinib The serum concentration of Erlotinib can be decreased when it is combined with Brigatinib. Bromazepam The metabolism of Bromazepam can be decreased when combined with Erlotinib. Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Erlotinib. Brompheniramine The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Erlotinib. Buclizine The risk or severity of QTc prolongation can be increased when Buclizine is combined with Erlotinib. Budesonide The serum concentration of Erlotinib can be decreased when it is combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Bupivacaine. Buprenorphine The metabolism of Erlotinib can be decreased when combined with Buprenorphine. Bupropion The metabolism of Erlotinib can be decreased when combined with Bupropion. Buserelin The risk or severity of QTc prolongation can be increased when Buserelin is combined with Erlotinib. Buspirone The metabolism of Erlotinib can be decreased when combined with Buspirone. Busulfan The metabolism of Busulfan can be decreased when combined with Erlotinib. Butacaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Butacaine. Butalbital The serum concentration of Erlotinib can be decreased when it is combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Erlotinib. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Erlotinib. Cabergoline The metabolism of Cabergoline can be decreased when combined with Erlotinib. Cabotegravir The metabolism of Cabotegravir can be decreased when combined with Erlotinib. Cabozantinib The metabolism of Erlotinib can be decreased when combined with Cabozantinib. Caffeine The metabolism of Erlotinib can be decreased when combined with Caffeine. Calcitriol The serum concentration of Erlotinib can be decreased when it is combined with Calcitriol. Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Canakinumab The metabolism of Erlotinib can be increased when combined with Canakinumab. Candesartan The metabolism of Erlotinib can be decreased when combined with Candesartan cilexetil. Candicidin The metabolism of Erlotinib can be decreased when combined with Candicidin. Cannabidiol The metabolism of Erlotinib can be decreased when combined with Cannabidiol. Capecitabine The serum concentration of Erlotinib can be increased when it is combined with Capecitabine. Capmatinib The serum concentration of Erlotinib can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Capsaicin. Carbamazepine The metabolism of Erlotinib can be increased when combined with Carbamazepine. Carbimazole The therapeutic efficacy of Carbimazole can be decreased when used in combination with Erlotinib. Carbinoxamine The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Erlotinib. Carmustine The metabolism of Erlotinib can be decreased when combined with Carmustine. Carvedilol The metabolism of Erlotinib can be decreased when combined with Carvedilol. Cefradine The serum concentration of Erlotinib can be decreased when it is combined with Cefradine. Celecoxib The metabolism of Erlotinib can be decreased when combined with Celecoxib. Celiprolol The metabolism of Erlotinib can be decreased when combined with Celiprolol. Cenobamate The serum concentration of Erlotinib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Erlotinib can be decreased when combined with Cephalexin. Ceritinib The metabolism of Erlotinib can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Cerivastatin can be decreased when combined with Erlotinib. Certolizumab The metabolism of Erlotinib can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Erlotinib. Cevimeline The metabolism of Erlotinib can be decreased when combined with Cevimeline. Chloramphenicol The metabolism of Erlotinib can be decreased when combined with Chloramphenicol. Chlorcyclizine The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Erlotinib. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Chloroprocaine. Chloroquine The metabolism of Erlotinib can be decreased when combined with Chloroquine. Chlorpheniramine The metabolism of Erlotinib can be decreased when combined with Chlorpheniramine. Chlorpromazine The serum concentration of Erlotinib can be decreased when it is combined with Chlorpromazine. Chlorprothixene The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Erlotinib. Chlorzoxazone The metabolism of Erlotinib can be decreased when combined with Chlorzoxazone. Cholecalciferol The metabolism of Erlotinib can be decreased when combined with Cholecalciferol. Ciclesonide The metabolism of Erlotinib can be decreased when combined with Ciclesonide. Cilostazol The metabolism of Cilostazol can be decreased when combined with Erlotinib. Cimetidine Cimetidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Cinacalcet The metabolism of Erlotinib can be decreased when combined with Cinacalcet. Cinchocaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Cinchocaine. Cinnarizine The metabolism of Erlotinib can be decreased when combined with Cinnarizine. Cinoxacin The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Erlotinib. Ciprofloxacin The serum concentration of Erlotinib can be increased when it is combined with Ciprofloxacin. Cisapride The metabolism of Erlotinib can be decreased when combined with Cisapride. Citalopram The metabolism of Erlotinib can be decreased when combined with Citalopram. Cladribine Erlotinib may decrease the excretion rate of Cladribine which could result in a higher serum level. Clarithromycin The metabolism of Erlotinib can be decreased when combined with Clarithromycin. Clemastine The metabolism of Erlotinib can be decreased when combined with Clemastine. Clevidipine The serum concentration of Erlotinib can be decreased when it is combined with Clevidipine. Clindamycin The metabolism of Erlotinib can be decreased when combined with Clindamycin. Clobazam The serum concentration of Erlotinib can be decreased when it is combined with Clobazam. Clobetasol The serum concentration of Erlotinib can be decreased when it is combined with Clobetasol propionate. Clofarabine Erlotinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. Clofazimine The metabolism of Erlotinib can be decreased when combined with Clofazimine. Clofibrate The serum concentration of Erlotinib can be decreased when it is combined with Clofibrate. Clomipramine The metabolism of Clomipramine can be decreased when combined with Erlotinib. Clonidine The metabolism of Clonidine can be decreased when combined with Erlotinib. Clopidogrel The metabolism of Erlotinib can be decreased when combined with Clopidogrel. Clozapine The serum concentration of Erlotinib can be decreased when it is combined with Clozapine. Cobicistat The metabolism of Erlotinib can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Erlotinib. Cocaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Cocaine. Codeine The metabolism of Erlotinib can be decreased when combined with Codeine. Colchicine The metabolism of Colchicine can be decreased when combined with Erlotinib. Conivaptan The metabolism of Erlotinib can be decreased when combined with Conivaptan. Conjugated estrogens The metabolism of Erlotinib can be decreased when combined with Conjugated estrogens. Copanlisib The metabolism of Copanlisib can be decreased when combined with Erlotinib. Corticotropin The serum concentration of Erlotinib can be decreased when it is combined with Corticotropin. Cortisone acetate The serum concentration of Erlotinib can be decreased when it is combined with Cortisone acetate. Crizotinib The metabolism of Erlotinib can be decreased when combined with Crizotinib. Curcumin The metabolism of Erlotinib can be decreased when combined with Curcumin. Cyclizine The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Erlotinib. Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Erlotinib. Cyclophosphamide The serum concentration of Erlotinib can be decreased when it is combined with Cyclophosphamide. Cyclosporine The metabolism of Erlotinib can be decreased when combined with Cyclosporine. Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Erlotinib. Cyproterone acetate The metabolism of Erlotinib can be increased when combined with Cyproterone acetate. Dabrafenib The serum concentration of Erlotinib can be decreased when it is combined with Dabrafenib. Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Erlotinib. Daclatasvir The metabolism of Erlotinib can be decreased when combined with Daclatasvir. Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Erlotinib. Dactinomycin Erlotinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Dalfopristin The metabolism of Erlotinib can be decreased when combined with Dalfopristin. Danazol The metabolism of Erlotinib can be decreased when combined with Danazol. Dapagliflozin The metabolism of Erlotinib can be decreased when combined with Dapagliflozin. Dapsone The metabolism of Erlotinib can be decreased when combined with Dapsone. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Erlotinib. Darifenacin The metabolism of Erlotinib can be decreased when combined with Darifenacin. Darolutamide Erlotinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. Darunavir The serum concentration of Erlotinib can be increased when it is combined with Darunavir. Dasabuvir The metabolism of Erlotinib can be decreased when combined with Dasabuvir. Dasatinib The metabolism of Erlotinib can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Erlotinib can be decreased when combined with Daunorubicin. Debrisoquine The metabolism of Erlotinib can be decreased when combined with Debrisoquine. Deferasirox The serum concentration of Erlotinib can be decreased when it is combined with Deferasirox. Deflazacort The metabolism of Erlotinib can be increased when combined with Deflazacort. Degarelix The risk or severity of QTc prolongation can be increased when Degarelix is combined with Erlotinib. Delafloxacin The serum concentration of Erlotinib can be decreased when it is combined with Delafloxacin. Delamanid Erlotinib may increase the QTc-prolonging activities of Delamanid. Delavirdine The metabolism of Erlotinib can be decreased when combined with Delavirdine. Desflurane The risk or severity of QTc prolongation can be increased when Desflurane is combined with Erlotinib. Desipramine The metabolism of Erlotinib can be decreased when combined with Desipramine. Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Erlotinib. Desvenlafaxine The metabolism of Erlotinib can be decreased when combined with Desvenlafaxine. Deutetrabenazine The metabolism of Erlotinib can be decreased when combined with Deutetrabenazine. Dexamethasone The metabolism of Erlotinib can be increased when combined with Dexamethasone. Dexamethasone The serum concentration of Erlotinib can be decreased when it is combined with Dexamethasone acetate. Dexbromphenir The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Erlotinib. Dexchlorphenira The metabolism of Erlotinib can be decreased when combined with Dexchlorpheniramine maleate. Dexfenfluramine The metabolism of Erlotinib can be decreased when combined with Dexfenfluramine. Dexibuprofen The metabolism of Erlotinib can be decreased when combined with Dexibuprofen. Dexlansoprazole Dexlansoprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Dexmedetomidine The metabolism of Erlotinib can be decreased when combined with Dexmedetomidine. Dextroamphetamine The metabolism of Erlotinib can be decreased when combined with Dextroamphetamine. Dextromethorphan The metabolism of Erlotinib can be decreased when combined with Dextromethorphan. Dextropropox The metabolism of Erlotinib can be decreased when combined with Dextropropoxyphene. Diacerein The metabolism of Erlotinib can be decreased when combined with Diacerein. Diazepam The metabolism of Erlotinib can be decreased when combined with Diazepam. Diclofenac The metabolism of Erlotinib can be decreased when combined with Diclofenac. Dicloxacillin The serum concentration of Erlotinib can be decreased when it is combined with Dicloxacillin. Dicoumarol The serum concentration of Dicoumarol can be increased when it is combined with Erlotinib. Diethylstilbestrol The metabolism of Erlotinib can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Erlotinib can be increased when combined with Difluocortolone. Digitoxin The metabolism of Digitoxin can be decreased when combined with Erlotinib. Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Erlotinib. Dihydralazine The metabolism of Erlotinib can be decreased when combined with Dihydralazine. Dihydrocodeine The metabolism of Erlotinib can be decreased when combined with Dihydrocodeine. Dihydroergocornine The metabolism of Erlotinib can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Erlotinib can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Erlotinib can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Erlotinib can be decreased when combined with Diltiazem. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Erlotinib. Dimethyl sulfoxide The metabolism of Erlotinib can be decreased when combined with Dimethyl sulfoxide. Diosmin The metabolism of Erlotinib can be decreased when combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Diphenhydramine. Disopyramide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Erlotinib. Disulfiram The metabolism of Erlotinib can be decreased when combined with Disulfiram. Docetaxel The metabolism of Docetaxel can be decreased when combined with Erlotinib. Dofetilide The metabolism of Dofetilide can be decreased when combined with Erlotinib. Dolasetron The metabolism of Erlotinib can be decreased when combined with Dolasetron. Dolutegravir Erlotinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. Domperidone The metabolism of Erlotinib can be decreased when combined with Domperidone. Donepezil The metabolism of Erlotinib can be decreased when combined with Donepezil. Doravirine The metabolism of Erlotinib can be decreased when combined with Doravirine. Dosulepin The metabolism of Erlotinib can be decreased when combined with Dosulepin. Doxazosin The metabolism of Erlotinib can be decreased when combined with Doxazosin. Doxepin Doxepin can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Erlotinib. Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Erlotinib. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Erlotinib. Dronedarone Erlotinib may increase the QTc-prolonging activities of Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Erlotinib. Drospirenone The metabolism of Erlotinib can be decreased when combined with Drospirenone. Duloxetine The metabolism of Erlotinib can be decreased when combined with Duloxetine. Dutasteride The metabolism of Erlotinib can be decreased when combined with Dutasteride. Duvelisib The metabolism of Erlotinib can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Dyclonine. Ebastine The metabolism of Erlotinib can be decreased when combined with Ebastine. Echinacea The metabolism of Erlotinib can be increased when combined with Echinacea. Efavirenz The metabolism of Erlotinib can be decreased when combined with Efavirenz. Elagolix The metabolism of Erlotinib can be decreased when combined with Elagolix. Elbasvir The metabolism of Erlotinib can be decreased when combined with Elbasvir. Eletriptan The metabolism of Erlotinib can be decreased when combined with Eletriptan. Elexacaftor The metabolism of Erlotinib can be decreased when combined with Elexacaftor. Eliglustat The metabolism of Eliglustat can be decreased when combined with Erlotinib. Eltrombopag The metabolism of Erlotinib can be decreased when combined with Eltrombopag. Elvitegravir The metabolism of Erlotinib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Erlotinib can be increased when combined with Emapalumab. medastine The risk or severity of QTc prolongation can be increased when Emedastine is combined with Erlotinib. Enasidenib The serum concentration of Erlotinib can be decreased when it is combined with Enasidenib. Encainide The metabolism of Erlotinib can be decreased when combined with Encainide. Encorafenib The metabolism of Erlotinib can be decreased when combined with Encorafenib. Enoxacin The metabolism of Erlotinib can be decreased when combined with Enoxacin. Entacapone The metabolism of Erlotinib can be decreased when combined with Entacapone. Entecavir The metabolism of Erlotinib can be decreased when combined with Entecavir. Entrectinib The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Entrectinib. Enzalutamide The metabolism of Erlotinib can be increased when combined with Enzalutamide. Epinastine Epinastine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Epinephrine The metabolism of Erlotinib can be decreased when combined with Epinephrine. Eplerenone The metabolism of Erlotinib can be decreased when combined with Eplerenone. Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Erlotinib. Ergotamine The metabolism of Erlotinib can be decreased when combined with Ergotamine. Eribulin The risk or severity of QTc prolongation can be increased when Eribulin is combined with Erlotinib. Ertugliflozin Erlotinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. Erythromycin The metabolism of Erlotinib can be decreased when combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Erlotinib. Escitalopram The serum concentration of Erlotinib can be increased when it is combined with Escitalopram. Esketamine The serum concentration of Erlotinib can be decreased when it is combined with Esketamine. Eslicarbazepine The serum concentration of Erlotinib can be decreased when it is combined with Eslicarbazepine. Eslicarbazepine acetate The serum concentration of Erlotinib can be decreased when it is combined with Eslicarbazepine acetate. Esmolol The metabolism of Erlotinib can be decreased when combined with Esmolol. Esomeprazole Esomeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Estetrol The metabolism of Erlotinib can be decreased when combined with Estetrol. Estradiol The metabolism of Erlotinib can be decreased when combined with Estradiol. Estradiol acetate The serum concentration of Erlotinib can be decreased when it is combined with Estradiol acetate. Estradiol benzoate The serum concentration of Erlotinib can be decreased when it is combined with Estradiol benzoate. Estradiol cypionate The serum concentration of Erlotinib can be decreased when it is combined with Estradiol cypionate. Estradiol dienanthate The serum concentration of Erlotinib can be decreased when it is combined with Estradiol dienanthate. Estradiol valerate The serum concentration of Erlotinib can be decreased when it is combined with Estradiol valerate. Estrone sulfate The metabolism of Erlotinib can be decreased when combined with Estrone sulfate. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Erlotinib. Etanercept The metabolism of Erlotinib can be increased when combined with Etanercept. Ethambutol The metabolism of Erlotinib can be decreased when combined with Ethambutol. Ethanol The serum concentration of Erlotinib can be decreased when it is combined with Ethanol. Ethinylestradiol The metabolism of Erlotinib can be decreased when combined with Ethinylestradiol. Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Erlotinib. Ethotoin The serum concentration of Erlotinib can be decreased when it is combined with Ethotoin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Etidocaine. Etoposide The serum concentration of Erlotinib can be decreased when it is combined with Etoposide. Etoricoxib The metabolism of Erlotinib can be decreased when combined with Etoricoxib. Etravirine The serum concentration of Erlotinib can be decreased when it is combined with Etravirine. Everolimus The metabolism of Everolimus can be decreased when combined with Erlotinib. Ezetimibe Erlotinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. Ezogabine The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Erlotinib. Famotidine Famotidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Favipiravir The metabolism of Erlotinib can be decreased when combined with Favipiravir. Febuxostat The metabolism of Febuxostat can be decreased when combined with Erlotinib. Fedratinib The metabolism of Erlotinib can be decreased when combined with Fedratinib. Felbamate The serum concentration of Erlotinib can be decreased when it is combined with Felbamate. Felodipine The metabolism of Erlotinib can be decreased when combined with Felodipine. Fenfluramine The metabolism of Erlotinib can be decreased when combined with Fenfluramine. Fenofibrate The metabolism of Erlotinib can be decreased when combined with Fenofibrate. Fentanyl The metabolism of Fentanyl can be decreased when combined with Erlotinib. Fesoterodine The metabolism of Erlotinib can be decreased when combined with Fesoterodine. Fexinidazole The risk or severity of adverse effects can be increased when Erlotinib is combined with Fexinidazole. Filgotinib The serum concentration of Erlotinib can be increased when it is combined with Filgotinib. Finasteride The metabolism of Erlotinib can be decreased when combined with Finasteride. Finerenone The serum concentration of Finerenone can be increased when it is combined with Erlotinib. Flecainide The metabolism of Erlotinib can be decreased when combined with Flecainide. Flucloxacillin The serum concentration of Erlotinib can be decreased when it is combined with Flucloxacillin. Fluconazole The metabolism of Erlotinib can be decreased when combined with Fluconazole. Fluindione The serum concentration of Fluindione can be increased when it is combined with Erlotinib. Flunarizine The metabolism of Erlotinib can be decreased when combined with Flunarizine. Flunisolide The serum concentration of Erlotinib can be decreased when it is combined with Flunisolide. Fluocinolone acetonide The serum concentration of Erlotinib can be decreased when it is combined with Fluocinolone acetonide. Fluocinonide The metabolism of Erlotinib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Erlotinib can be increased when combined with Fluocortolone. Fluorouracil The metabolism of Fluorouracil can be decreased when combined with Erlotinib. Fluoxetine The serum concentration of Erlotinib can be increased when it is combined with Fluoxetine. Flupentixol The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Flupentixol. Fluphenazine The metabolism of Erlotinib can be decreased when combined with Fluphenazine. Flurbiprofen The metabolism of Flurbiprofen can be decreased when combined with Erlotinib. Fluspirilene The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Erlotinib. Flutamide The metabolism of Erlotinib can be decreased when combined with Flutamide. Fluticasone The metabolism of Erlotinib can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Erlotinib can be increased when combined with Fluticasone furoate. Fluticasone The metabolism of Erlotinib can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Erlotinib. Fluvoxamine The metabolism of Erlotinib can be decreased when combined with Fluvoxamine. Folic acid Erlotinib may decrease the excretion rate of Folic acid which could result in a higher serum level. Follitropin The therapeutic efficacy of Follitropin can be decreased when used in combination with Erlotinib. Formestane The serum concentration of Erlotinib can be decreased when it is combined with Formestane. Formoterol The metabolism of Erlotinib can be decreased when combined with Formoterol. Fosamprenavir The metabolism of Erlotinib can be decreased when combined with Fosamprenavir. Fosaprepitant The serum concentration of Erlotinib can be decreased when it is combined with Fosaprepitant. Foscarnet The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Erlotinib. Fosnetupitant The metabolism of Erlotinib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Erlotinib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Erlotinib can be decreased when combined with Fostamatinib. Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Erlotinib. Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Erlotinib. Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Erlotinib. Furosemide The metabolism of Furosemide can be decreased when combined with Erlotinib. Fusidic acid The metabolism of Erlotinib can be decreased when combined with Fusidic acid. Gadobenic acid The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Erlotinib. Galantamine The metabolism of Erlotinib can be decreased when combined with Galantamine. Gatifloxacin The metabolism of Erlotinib can be decreased when combined with Gatifloxacin. Gefitinib The metabolism of Erlotinib can be decreased when combined with Gefitinib. Gemfibrozil The metabolism of Erlotinib can be decreased when combined with Gemfibrozil. Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Erlotinib. Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Erlotinib. Ginkgo biloba The metabolism of Erlotinib can be decreased when combined with Ginkgo biloba. Givosiran The serum concentration of Erlotinib can be increased when it is combined with Givosiran. Glasdegib The metabolism of Erlotinib can be decreased when combined with Glasdegib. Glecaprevir The metabolism of Erlotinib can be decreased when combined with Glecaprevir. Glipizide The metabolism of Glipizide can be decreased when combined with Erlotinib. Glyburide The metabolism of Erlotinib can be decreased when combined with Glyburide. Glycerol The serum concentration of Erlotinib can be decreased when it is combined with Glycerol phenylbutyrate. Golimumab The metabolism of Erlotinib can be increased when combined with Golimumab. Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erlotinib. Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Erlotinib. Grepafloxacin The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Erlotinib. Griseofulvin The serum concentration of Erlotinib can be decreased when it is combined with Griseofulvin. Guanabenz The metabolism of Guanabenz can be decreased when combined with Erlotinib. Halofantrine The metabolism of Erlotinib can be decreased when combined with Halofantrine. Haloperidol The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Haloperidol. Histrelin The risk or severity of QTc prolongation can be increased when Histrelin is combined with Erlotinib. Hydralazine The metabolism of Erlotinib can be decreased when combined with Hydralazine. Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Erlotinib. Hydrocodone The metabolism of Erlotinib can be decreased when combined with Hydrocodone. Hydrocortamate The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortamate. Hydrocortisone The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortisone. Hydrocortisone acet The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortisone acetate. Hydrocortisone bu The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortisone butyrate. Hydrocortisone The metabolism of Erlotinib can be decreased when combined with Hydrocortisone cypionate. Hydrocortisone The metabolism of Erlotinib can be decreased when combined with Hydrocortisone phosphate. Hydrocortisone The serum concentration of Erlotinib can be decreased when it is combined with Hydrocortisone succinate. Hydrotalcite Hydrotalcite can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Hydroxychloroquine The metabolism of Erlotinib can be decreased when combined with Hydroxychloroquine. Hydroxyprogeste The metabolism of Erlotinib can be decreased when combined with Hydroxyprogesterone caproate. Hydroxyzine The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Hydroxyzine. Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Erlotinib. Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erlotinib. Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Erlotinib. Ibuprofen The metabolism of Erlotinib can be decreased when combined with Ibuprofen. Ibutilide The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Erlotinib. Idarubicin The metabolism of Erlotinib can be decreased when combined with Idarubicin. Idelalisib The metabolism of Idelalisib can be decreased when combined with Erlotinib. Ifosfamide The serum concentration of Erlotinib can be decreased when it is combined with Ifosfamide. Iloperidone The metabolism of Iloperidone can be decreased when combined with Erlotinib. Imatinib The serum concentration of Erlotinib can be increased when it is combined with Imatinib. Imipramine The metabolism of Erlotinib can be decreased when combined with Imipramine. Indacaterol The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Erlotinib. Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Erlotinib. Indinavir The metabolism of Erlotinib can be decreased when combined with Indinavir. Indomethacin The metabolism of Indomethacin can be decreased when combined with Erlotinib. Infigratinib The metabolism of Erlotinib can be decreased when combined with Infigratinib. Infliximab The metabolism of Erlotinib can be increased when combined with Infliximab. Inotersen The risk or severity of QTc prolongation can be increased when Inotersen is combined with Erlotinib. Insulin beef The metabolism of Erlotinib can be increased when combined with Insulin beef. Insulin pork The metabolism of Erlotinib can be increased when combined with Insulin pork. Interferon alfa-2a The metabolism of Erlotinib can be decreased when combined with Interferon alfa-2a. Interferon alfa-2b The metabolism of Erlotinib can be decreased when combined with Interferon alfa-2b. Interferon alfa-n1 The metabolism of Erlotinib can be decreased when combined with Interferon alfa-n1. Interferon alfa-n3 The metabolism of Erlotinib can be decreased when combined with Interferon alfa-n3. Interferon alfa The metabolism of Erlotinib can be decreased when combined with Interferon alfacon-1. Interferon beta-1a The metabolism of Erlotinib can be decreased when combined with Interferon beta-1a. Interferon beta-1b The metabolism of Erlotinib can be decreased when combined with Interferon beta-1b. Interferon The metabolism of Erlotinib can be decreased when combined with Interferon gamma-1b. Ipecac The metabolism of Erlotinib can be decreased when combined with Ipecac. Irbesartan The metabolism of Erlotinib can be decreased when combined with Irbesartan. Irinotecan The risk or severity of neutropenia can be increased when Erlotinib is combined with Irinotecan. Isavuconazole The serum concentration of Erlotinib can be decreased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Erlotinib can be decreased when it is combined with Isavuconazonium. Isoflurane The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Erlotinib. Isoniazid The metabolism of Erlotinib can be decreased when combined with Isoniazid. Isradipine The metabolism of Erlotinib can be decreased when combined with Isradipine. Istradefylline The metabolism of Erlotinib can be decreased when combined with Istradefylline. Itraconazole The metabolism of Erlotinib can be decreased when combined with Itraconazole. Ivabradine The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Ivabradine. Ivacaftor The metabolism of Erlotinib can be decreased when combined with Ivacaftor. Ivermectin Erlotinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. Ivosidenib The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Ivosidenib. Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Erlotinib. Ixazomib The metabolism of Ixazomib can be decreased when combined with Erlotinib. Ketamine The serum concentration of Erlotinib can be decreased when it is combined with Ketamine. Ketazolam The metabolism of Erlotinib can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Erlotinib can be decreased when combined with Ketoconazole. Ketoprofen The metabolism of Erlotinib can be decreased when combined with Ketoprofen. Ketorolac The metabolism of Erlotinib can be decreased when combined with Ketorolac. Labetalol The metabolism of Erlotinib can be decreased when combined with Labetalol. Lacidipine The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Erlotinib. Lacosamide The metabolism of Erlotinib can be decreased when combined with Lacosamide. Lamivudine Erlotinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Erlotinib. Lanreotide The metabolism of Erlotinib can be decreased when combined with Lanreotide. Lansoprazole Lansoprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Lapatinib The metabolism of Erlotinib can be decreased when combined with Lapatinib. Lefamulin Lefamulin may increase the QTc-prolonging activities of Erlotinib. Leflunomide The serum concentration of Erlotinib can be decreased when it is combined with Leflunomide. Lemborexant The metabolism of Erlotinib can be decreased when combined with Lemborexant. Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Erlotinib. Lercanidipine The metabolism of Erlotinib can be decreased when combined with Lercanidipine. Lesinurad The metabolism of Erlotinib can be increased when combined with Lesinurad. Letermovir The metabolism of Erlotinib can be decreased when combined with Letermovir. Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erlotinib. Levacetylmeth The metabolism of Levacetylmethadol can be decreased when combined with Erlotinib. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Erlotinib. Levobetaxolol The metabolism of Erlotinib can be decreased when combined with Levobetaxolol. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Erlotinib. Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Erlotinib. Levofloxacin The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Erlotinib. Levoketoconazole The metabolism of Erlotinib can be decreased when combined with Levoketoconazole. Levomenthol The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Erlotinib. Levomilnacipran The metabolism of Erlotinib can be decreased when combined with Levomilnacipran. Levonorgestrel The metabolism of Erlotinib can be decreased when combined with Levonorgestrel. Levosimendan The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Erlotinib. Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Erlotinib. Lidocaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Erlotinib. Linagliptin The metabolism of Erlotinib can be decreased when combined with Linagliptin. Linzagolix The serum concentration of Erlotinib can be increased when it is combined with Linzagolix. Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Erlotinib. Liotrix The therapeutic efficacy of Liotrix can be decreased when used in combination with Erlotinib. Lisdexamfetamine The metabolism of Erlotinib can be decreased when combined with Lisdexamfetamine. Lisuride The metabolism of Erlotinib can be decreased when combined with Lisuride. Lofexidine The metabolism of Erlotinib can be decreased when combined with Lofexidine. Lomefloxacin The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Erlotinib. Lomitapide The metabolism of Erlotinib can be decreased when combined with Lomitapide. Lonafarnib The metabolism of Erlotinib can be decreased when combined with Lonafarnib. Lonapegsomatr The metabolism of Erlotinib can be increased when combined with Lonapegsomatropin. Loperamide The metabolism of Loperamide can be decreased when combined with Erlotinib. Lopinavir The metabolism of Erlotinib can be decreased when combined with Lopinavir. Loratadine The metabolism of Erlotinib can be decreased when combined with Loratadine. Lorcaserin The metabolism of Erlotinib can be decreased when combined with Lorcaserin. Lorlatinib The serum concentration of Erlotinib can be decreased when it is combined with Lorlatinib. Lorpiprazole The metabolism of Erlotinib can be decreased when combined with Lorpiprazole. Losartan The metabolism of Erlotinib can be decreased when combined with Losartan. Lovastatin The metabolism of Lovastatin can be decreased when combined with Erlotinib. Lumacaftor The metabolism of Erlotinib can be increased when combined with Lumacaftor. Lumateperone The serum concentration of Lumateperone can be increased when it is combined with Erlotinib. Lumefantrine The metabolism of Erlotinib can be decreased when combined with Lumefantrine. Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Erlotinib. Lusutrombopag Erlotinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. Macimorelin The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Macimorelin. Magaldrate Magaldrate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium Magnesium carbonate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium Magnesium hydroxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium oxide Magnesium oxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium silicate Magnesium silicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Magnesium Magnesium trisilicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Manidipine The metabolism of Erlotinib can be decreased when combined with Manidipine. Maprotiline The metabolism of Erlotinib can be decreased when combined with Maprotiline. Mavacamten The serum concentration of Erlotinib can be decreased when it is combined with Mavacamten. Meclizine The metabolism of Erlotinib can be decreased when combined with Meclizine. Medroxyprogester The serum concentration of Erlotinib can be decreased when it is combined with Medroxyprogesterone acetate. Mefenamic acid The metabolism of Mefenamic acid can be decreased when combined with Erlotinib. Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Erlotinib. Melatonin The metabolism of Melatonin can be decreased when combined with Erlotinib. Meloxicam The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Meloxicam. Meperidine The metabolism of Erlotinib can be decreased when combined with Meperidine. Mephenytoin The metabolism of Erlotinib can be decreased when combined with Mephenytoin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Mepivacaine. Meprednisone The metabolism of Erlotinib can be increased when combined with Meprednisone. Mepyramine The metabolism of Erlotinib can be decreased when combined with Mepyramine. Mesoridazine The metabolism of Erlotinib can be decreased when combined with Mesoridazine. Mestranol The metabolism of Erlotinib can be decreased when combined with Mestranol. Metamfetamine The metabolism of Erlotinib can be decreased when combined with Metamfetamine. Methadone The metabolism of Erlotinib can be decreased when combined with Methadone. Methantheline Methantheline can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Methimazole The metabolism of Erlotinib can be decreased when combined with Methimazole. Methotrexate The metabolism of Methotrexate can be decreased when combined with Erlotinib. Methotrimeprazine The metabolism of Erlotinib can be decreased when combined with Methotrimeprazine. Methoxsalen The metabolism of Erlotinib can be decreased when combined with Methoxsalen. Methoxy The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Erlotinib. Methoxyflurane The metabolism of Erlotinib can be decreased when combined with Methoxyflurane. Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Erlotinib. Methylene blue The metabolism of Erlotinib can be decreased when combined with Methylene blue. Methylergometrine The metabolism of Erlotinib can be decreased when combined with Methylergometrine. Methylphenobarbital The serum concentration of Erlotinib can be decreased when it is combined with Methylphenobarbital. Methylprednisolone The serum concentration of Erlotinib can be decreased when it is combined with Methylprednisolone. Methylprednisone The metabolism of Erlotinib can be decreased when combined with Methylprednisone. Methysergide The metabolism of Erlotinib can be decreased when combined with Methysergide. Metoclopramide The metabolism of Erlotinib can be decreased when combined with Metoclopramide. Metoprolol The metabolism of Erlotinib can be decreased when combined with Metoprolol. Metreleptin The metabolism of Erlotinib can be increased when combined with Metreleptin. Metronidazole The metabolism of Erlotinib can be decreased when combined with Metronidazole. Metyrapone The serum concentration of Erlotinib can be decreased when it is combined with Metyrapone. Mexiletine The metabolism of Erlotinib can be decreased when combined with Mexiletine. Mianserin The metabolism of Erlotinib can be decreased when combined with Mianserin. Miconazole The metabolism of Erlotinib can be decreased when combined with Miconazole. Midazolam The serum concentration of Midazolam can be increased when it is combined with Erlotinib. Midostaurin The metabolism of Erlotinib can be decreased when combined with Midostaurin. Mifepristone The serum concentration of Erlotinib can be increased when it is combined with Mifepristone. Migalastat The metabolism of Migalastat can be decreased when combined with Erlotinib. Milnacipran The metabolism of Erlotinib can be decreased when combined with Milnacipran. Minaprine The metabolism of Erlotinib can be decreased when combined with Minaprine. Minoxidil The metabolism of Minoxidil can be decreased when combined with Erlotinib. Miocamycin The metabolism of Erlotinib can be decreased when combined with Miocamycin. Mirabegron The serum concentration of Erlotinib can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Erlotinib can be decreased when combined with Mirtazapine. Mitapivat The serum concentration of Erlotinib can be decreased when it is combined with Mitapivat. Mitotane The metabolism of Erlotinib can be increased when combined with Mitotane. Mitoxantrone Erlotinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. Mizolastine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Erlotinib. Mobocertinib The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Mobocertinib. Moclobemide The metabolism of Erlotinib can be decreased when combined with Moclobemide. Modafinil The serum concentration of Erlotinib can be decreased when it is combined with Modafinil. Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Erlotinib. Mometasone The metabolism of Erlotinib can be increased when combined with Mometasone furoate. Montelukast The metabolism of Erlotinib can be decreased when combined with Montelukast. Moricizine The risk or severity of QTc prolongation can be increased when Moricizine is combined with Erlotinib. Morphine The metabolism of Erlotinib can be decreased when combined with Morphine. Mosunetuzumab The metabolism of Erlotinib can be decreased when combined with Mosunetuzumab. Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Erlotinib. Mycophenolate The metabolism of Erlotinib can be decreased when combined with Mycophenolate mofetil. Mycophenolic acid The metabolism of Mycophenolic acid can be decreased when combined with Erlotinib. Nabumetone The metabolism of Erlotinib can be decreased when combined with Nabumetone. Nadolol The metabolism of Erlotinib can be decreased when combined with Nadolol. Nafcillin The serum concentration of Erlotinib can be decreased when it is combined with Nafcillin. Nalidixic acid The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Erlotinib. Naloxone The metabolism of Erlotinib can be decreased when combined with Naloxone. Naltrexone The metabolism of Naltrexone can be decreased when combined with Erlotinib. Naproxen The metabolism of Erlotinib can be decreased when combined with Naproxen. Nateglinide The metabolism of Erlotinib can be decreased when combined with Nateglinide. Nebivolol The metabolism of Erlotinib can be decreased when combined with Nebivolol. Nefazodone The metabolism of Erlotinib can be decreased when combined with Nefazodone. Nelfinavir The metabolism of Erlotinib can be decreased when combined with Nelfinavir. Neratinib The metabolism of Neratinib can be decreased when combined with Erlotinib. Netupitant The metabolism of Erlotinib can be decreased when combined with Netupitant. Nevirapine The metabolism of Erlotinib can be decreased when combined with Nevirapine. Niacin The metabolism of Erlotinib can be decreased when combined with Niacin. Nicardipine The metabolism of Erlotinib can be decreased when combined with Nicardipine. Nicergoline The metabolism of Erlotinib can be decreased when combined with Nicergoline. Niclosamide The metabolism of Erlotinib can be decreased when combined with Niclosamide. Nifedipine The serum concentration of Erlotinib can be decreased when it is combined with Nifedipine. Nilotinib The metabolism of Erlotinib can be decreased when combined with Nilotinib. Nilutamide The metabolism of Erlotinib can be decreased when combined with Nilutamide. Nilvadipine The metabolism of Erlotinib can be decreased when combined with Nilvadipine. Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Erlotinib. Nintedanib The metabolism of Erlotinib can be decreased when combined with Nintedanib. Nisoldipine The metabolism of Erlotinib can be decreased when combined with Nisoldipine. Nitrendipine The metabolism of Erlotinib can be decreased when combined with Nitrendipine. Nitrofurantoin Erlotinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. Nizatidine Nizatidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Norethisterone The metabolism of Erlotinib can be decreased when combined with Norethisterone. Norfloxacin The metabolism of Erlotinib can be decreased when combined with Norfloxacin. Norgestimate The serum concentration of Erlotinib can be decreased when it is combined with Norgestimate. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Erlotinib. Noscapine The metabolism of Erlotinib can be decreased when combined with Noscapine. Obeticholic acid The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Erlotinib. Octreotide The serum concentration of Erlotinib can be increased when it is combined with Octreotide. Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Erlotinib. Olanzapine Olanzapine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Olaparib The metabolism of Erlotinib can be decreased when combined with Olaparib. Oliceridine The metabolism of Erlotinib can be decreased when combined with Oliceridine. Olodaterol The metabolism of Erlotinib can be decreased when combined with Olodaterol. Ombitasvir The metabolism of Erlotinib can be decreased when combined with Ombitasvir. Omeprazole Omeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Ondansetron The metabolism of Erlotinib can be decreased when combined with Ondansetron. Opium The metabolism of Erlotinib can be decreased when combined with Opium. Oritavancin The serum concentration of Erlotinib can be decreased when it is combined with Oritavancin. Orphenadrine The metabolism of Erlotinib can be decreased when combined with Orphenadrine. Osilodrostat The serum concentration of Erlotinib can be increased when it is combined with Osilodrostat. Osimertinib The serum concentration of Erlotinib can be decreased when it is combined with Osimertinib. Ospemifene The metabolism of Erlotinib can be decreased when combined with Ospemifene. Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Erlotinib. Oxamniquine The metabolism of Erlotinib can be decreased when combined with Oxamniquine. Oxatomide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Erlotinib. Oxcarbazepine The serum concentration of Erlotinib can be decreased when it is combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Oxetacaine. Oxprenolol The metabolism of Erlotinib can be decreased when combined with Oxprenolol. Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Erlotinib. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Oxybuprocaine. Oxybutynin The metabolism of Erlotinib can be decreased when combined with Oxybutynin. Oxycodone The metabolism of Erlotinib can be decreased when combined with Oxycodone. Oxymorphone The metabolism of Erlotinib can be decreased when combined with Oxymorphone. Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erlotinib. Ozanimod The metabolism of Ozanimod can be decreased when combined with Erlotinib. Paclitaxel The serum concentration of Erlotinib can be decreased when it is combined with Paclitaxel. Pacritinib The serum concentration of Erlotinib can be increased when it is combined with Pacritinib. Palbociclib The metabolism of Erlotinib can be decreased when combined with Palbociclib. Paliperidone The metabolism of Erlotinib can be decreased when combined with Paliperidone. Palonosetron The metabolism of Erlotinib can be decreased when combined with Palonosetron. Panobinostat The metabolism of Erlotinib can be decreased when combined with Panobinostat. Pantoprazole Pantoprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Erlotinib. Paramethadione The metabolism of Erlotinib can be decreased when combined with Paramethadione. Parathyroid hormone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Erlotinib. Paritaprevir The metabolism of Erlotinib can be decreased when combined with Paritaprevir. Paroxetine The metabolism of Erlotinib can be decreased when combined with Paroxetine. Pasireotide The metabolism of Erlotinib can be decreased when combined with Pasireotide. Pazopanib The metabolism of Erlotinib can be decreased when combined with Pazopanib. Pefloxacin The metabolism of Erlotinib can be decreased when combined with Pefloxacin. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Erlotinib. Peginterferon a The metabolism of Erlotinib can be decreased when combined with Peginterferon alfa-2a. Peginterferon The serum concentration of Erlotinib can be increased when it is combined with Peginterferon alfa-2b. Pegvisomant The serum concentration of Erlotinib can be decreased when it is combined with Pegvisomant. Pemetrexed The metabolism of Pemetrexed can be decreased when combined with Erlotinib. Penbutolol The metabolism of Erlotinib can be decreased when combined with Penbutolol. Penciclovir The metabolism of Erlotinib can be decreased when combined with Penciclovir. Pentamidine The metabolism of Erlotinib can be decreased when combined with Pentamidine. Pentobarbital The metabolism of Erlotinib can be increased when combined with Pentobarbital. Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Erlotinib. Perampanel The serum concentration of Erlotinib can be decreased when it is combined with Perampanel. Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Erlotinib. Perhexiline The metabolism of Erlotinib can be decreased when combined with Perhexiline. Perphenazine The metabolism of Erlotinib can be decreased when combined with Perphenazine. Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Erlotinib. Phenformin The metabolism of Erlotinib can be decreased when combined with Phenformin. Phenindione The serum concentration of Phenindione can be increased when it is combined with Erlotinib. Pheniramine The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Erlotinib. Phenobarbital The metabolism of Erlotinib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Phenol. Phenprocoumon The serum concentration of Phenprocoumon can be increased when it is combined with Erlotinib. Phenylbutazone The serum concentration of Erlotinib can be decreased when it is combined with Phenylbutazone. Phenylbutyric acid The metabolism of Erlotinib can be decreased when combined with Phenylbutyric acid. Phenylephrine The metabolism of Erlotinib can be increased when combined with Phenylephrine. Phenytoin The metabolism of Erlotinib can be increased when combined with Phenytoin. Pibrentasvir Erlotinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. Pimavanserin The metabolism of Erlotinib can be decreased when combined with Pimavanserin. Pimozide The metabolism of Pimozide can be decreased when combined with Erlotinib. Pinaverium The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Erlotinib. Pindolol The metabolism of Erlotinib can be decreased when combined with Pindolol. Pioglitazone The serum concentration of Pioglitazone can be increased when it is combined with Erlotinib. Piperaquine The metabolism of Erlotinib can be decreased when combined with Piperaquine. Piperazine The metabolism of Erlotinib can be decreased when combined with Piperazine. Pipotiazine The metabolism of Erlotinib can be decreased when combined with Pipotiazine. Pirfenidone The metabolism of Erlotinib can be decreased when combined with Pirfenidone. Piroxicam The metabolism of Erlotinib can be decreased when combined with Piroxicam. Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Erlotinib. Pitolisant The serum concentration of Erlotinib can be decreased when it is combined with Pitolisant. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Erlotinib. Ponatinib The metabolism of Ponatinib can be decreased when combined with Erlotinib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Erlotinib. Posaconazole The metabolism of Erlotinib can be decreased when combined with Posaconazole. Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Erlotinib. Potassium The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Erlotinib. Practolol The metabolism of Erlotinib can be decreased when combined with Practolol. Pralatrexate Erlotinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralsetinib The serum concentration of Erlotinib can be decreased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Pramocaine. Pravastatin The metabolism of Pravastatin can be decreased when combined with Erlotinib. Praziquantel The metabolism of Erlotinib can be decreased when combined with Praziquantel. Prazosin Erlotinib may decrease the excretion rate of Prazosin which could result in a higher serum level. Prednisolone The serum concentration of Erlotinib can be decreased when it is combined with Prednisolone. Prednisolone The serum concentration of Erlotinib can be decreased when it is combined with Prednisolone acetate. Prednisolone phosphate The metabolism of Erlotinib can be increased when combined with Prednisolone phosphate. Prednisone The metabolism of Erlotinib can be increased when combined with Prednisone acetate. Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Erlotinib. Prenylamine The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Erlotinib. Pretomanid The metabolism of Erlotinib can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Prilocaine. Primaquine The metabolism of Erlotinib can be decreased when combined with Primaquine. Primidone The metabolism of Erlotinib can be increased when combined with Primidone. Probenecid The serum concentration of Erlotinib can be decreased when it is combined with Probenecid. Probucol The risk or severity of QTc prolongation can be increased when Probucol is combined with Erlotinib. Procainamide The metabolism of Procainamide can be decreased when combined with Erlotinib. Procaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Procaine. Prochlorperazine The metabolism of Erlotinib can be decreased when combined with Prochlorperazine. Progesterone The serum concentration of Erlotinib can be decreased when it is combined with Progesterone. Proguanil The metabolism of Erlotinib can be decreased when combined with Proguanil. Promazine The metabolism of Erlotinib can be decreased when combined with Promazine. Promethazine Promethazine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Propafenone The metabolism of Erlotinib can be decreased when combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Proparacaine. Propofol The metabolism of Erlotinib can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Propoxycaine. Propranolol The metabolism of Erlotinib can be decreased when combined with Propranolol. Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Erlotinib. Protirelin The therapeutic efficacy of Protirelin can be decreased when used in combination with Erlotinib. Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Erlotinib. Prucalopride The metabolism of Prucalopride can be decreased when combined with Erlotinib. Pyrimethamine The metabolism of Erlotinib can be decreased when combined with Pyrimethamine. Quetiapine The metabolism of Erlotinib can be decreased when combined with Quetiapine. Quinidine The metabolism of Erlotinib can be decreased when combined with Quinidine. Quinine The serum concentration of Erlotinib can be decreased when it is combined with Quinine. Quinupristin The metabolism of Erlotinib can be decreased when combined with Quinupristin. Rabeprazole Rabeprazole can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Raloxifene The metabolism of Erlotinib can be decreased when combined with Raloxifene. Raltegravir The metabolism of Raltegravir can be decreased when combined with Erlotinib. Ramelteon The metabolism of Ramelteon can be decreased when combined with Erlotinib. Ranitidine Ranitidine can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Ranolazine The serum concentration of Erlotinib can be increased when it is combined with Ranolazine. Rasagiline The metabolism of Rasagiline can be decreased when combined with Erlotinib. Reboxetine The metabolism of Erlotinib can be decreased when combined with Reboxetine. Regorafenib The metabolism of Regorafenib can be decreased when combined with Erlotinib. Relugolix The metabolism of Erlotinib can be decreased when combined with Relugolix. Remdesivir The metabolism of Erlotinib can be decreased when combined with Remdesivir. Remoxipride The metabolism of Erlotinib can be decreased when combined with Remoxipride. Repaglinide The metabolism of Erlotinib can be decreased when combined with Repaglinide. Reserpine The metabolism of Erlotinib can be increased when combined with Reserpine. Retapamulin The metabolism of Retapamulin can be decreased when combined with Erlotinib. Revefenacin The metabolism of Erlotinib can be decreased when combined with Revefenacin. Ribociclib The metabolism of Erlotinib can be decreased when combined with Ribociclib. Rifabutin The serum concentration of Erlotinib can be decreased when it is combined with Rifabutin. Rifampicin The metabolism of Erlotinib can be increased when combined with Rifampicin. Rifamycin The metabolism of Erlotinib can be increased when combined with Rifamycin. Rifapentine The metabolism of Erlotinib can be increased when combined with Rifapentine. Rifaximin The serum concentration of Erlotinib can be decreased when it is combined with Rifaximin. Rilonacept The metabolism of Erlotinib can be increased when combined with Rilonacept. Rilpivirine The metabolism of Erlotinib can be decreased when combined with Rilpivirine. Riluzole Erlotinib may decrease the excretion rate of Riluzole which could result in a higher serum level. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Erlotinib. Riociguat The metabolism of Erlotinib can be decreased when combined with Riociguat. Ripretinib Erlotinib may decrease the excretion rate of Ripretinib which could result in a higher serum level. Risperidone The metabolism of Erlotinib can be decreased when combined with Risperidone. Ritonavir The metabolism of Erlotinib can be decreased when combined with Ritonavir. Rivaroxaban The metabolism of Erlotinib can be decreased when combined with Rivaroxaban. Rofecoxib The serum concentration of Erlotinib can be decreased when it is combined with Rofecoxib. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Erlotinib. Rolapitant The metabolism of Erlotinib can be decreased when combined with Rolapitant. Romidepsin The metabolism of Romidepsin can be decreased when combined with Erlotinib. Ropeginterferon The metabolism of Erlotinib can be decreased when combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Ropivacaine. Rosiglitazone The metabolism of Erlotinib can be decreased when combined with Rosiglitazone. Rosoxacin The metabolism of Erlotinib can be decreased when combined with Rosoxacin. Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Erlotinib. Rotigotine The metabolism of Erlotinib can be decreased when combined with Rotigotine. Roxadustat The metabolism of Roxadustat can be decreased when combined with Erlotinib. Roxithromycin The metabolism of Erlotinib can be decreased when combined with Roxithromycin. Rucaparib The metabolism of Erlotinib can be decreased when combined with Rucaparib. Rufinamide The serum concentration of Erlotinib can be decreased when it is combined with Rufinamide. Rupatadine The metabolism of Erlotinib can be decreased when combined with Rupatadine. Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Erlotinib. Sacituzumab The serum concentration of Sacituzumab govitecan can be increased when it is combined with Erlotinib. Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Erlotinib. Salmeterol The metabolism of Erlotinib can be decreased when combined with Salmeterol. Salmon calcitonin The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Erlotinib. Saquinavir The metabolism of Erlotinib can be decreased when combined with Saquinavir. Sarilumab The serum concentration of Erlotinib can be decreased when it is combined with Sarilumab. Satralizumab The serum concentration of Erlotinib can be decreased when it is combined with Satralizumab. Saxagliptin The metabolism of Erlotinib can be decreased when combined with Saxagliptin. Secobarbital The serum concentration of Erlotinib can be decreased when it is combined with Secobarbital. Secukinumab The metabolism of Erlotinib can be increased when combined with Secukinumab. Selegiline The metabolism of Erlotinib can be decreased when combined with Selegiline. Selexipag The metabolism of Erlotinib can be decreased when combined with Selexipag. Selpercatinib The serum concentration of Erlotinib can be increased when it is combined with Selpercatinib. Selumetinib The metabolism of Erlotinib can be decreased when combined with Selumetinib. Sertindole The metabolism of Erlotinib can be decreased when combined with Sertindole. Sertraline The metabolism of Erlotinib can be decreased when combined with Sertraline. Sevoflurane The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Erlotinib. Sildenafil The metabolism of Erlotinib can be decreased when combined with Sildenafil. Siltuximab The serum concentration of Erlotinib can be decreased when it is combined with Siltuximab. Simeprevir The metabolism of Erlotinib can be decreased when combined with Simeprevir. Simvastatin The metabolism of Simvastatin can be decreased when combined with Erlotinib. Siponimod The metabolism of Siponimod can be decreased when combined with Erlotinib. Sirolimus The metabolism of Sirolimus can be decreased when combined with Erlotinib. Sitagliptin The metabolism of Erlotinib can be decreased when combined with Sitagliptin. Sitaxentan The metabolism of Erlotinib can be decreased when combined with Sitaxentan. Sodium Sodium bicarbonate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Sodium zirconium Sodium zirconium cyclosilicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Sofosbuvir Erlotinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solifenacin The metabolism of Erlotinib can be decreased when combined with Solifenacin. Somapacitan The metabolism of Erlotinib can be increased when combined with Somapacitan. Somatostatin The metabolism of Erlotinib can be decreased when combined with Somatostatin. Somatotropin The metabolism of Erlotinib can be increased when combined with Somatotropin. Somatrem The metabolism of Erlotinib can be increased when combined with Somatrem. Somatrogon The metabolism of Erlotinib can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be decreased when combined with Erlotinib. Sorafenib The metabolism of Sorafenib can be decreased when combined with Erlotinib. Sotalol The metabolism of Erlotinib can be decreased when combined with Sotalol. Sotorasib The serum concentration of Erlotinib can be decreased when it is combined with Sotorasib. Sparfloxacin The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Sparfloxacin. Spironolactone The metabolism of Erlotinib can be decreased when combined with Spironolactone. St. John's Wort The metabolism of Erlotinib can be increased when combined with St. John's Wort. Stiripentol The metabolism of Erlotinib can be decreased when combined with Stiripentol. Sulfadiazine The metabolism of Erlotinib can be decreased when combined with Sulfadiazine. Sulfamethoxazole The metabolism of Erlotinib can be decreased when combined with Sulfamethoxazole. Sulfaphenazole The metabolism of Erlotinib can be decreased when combined with Sulfaphenazole. Sulfasalazine Erlotinib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. Sulfinpyrazone The serum concentration of Erlotinib can be decreased when it is combined with Sulfinpyrazone. Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Erlotinib. Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Erlotinib. Sultopride The risk or severity of QTc prolongation can be increased when Sultopride is combined with Erlotinib. Sumatriptan Erlotinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. Sunitinib The metabolism of Sunitinib can be decreased when combined with Erlotinib. Suvorexant The metabolism of Erlotinib can be decreased when combined with Suvorexant. Tacrine The metabolism of Erlotinib can be decreased when combined with Tacrine. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Erlotinib. Tadalafil The metabolism of Erlotinib can be decreased when combined with Tadalafil. Tafenoquine The metabolism of Erlotinib can be decreased when combined with Tafenoquine. Talazoparib Erlotinib may decrease the excretion rate of Talazoparib which could result in a higher serum level. Tamoxifen The serum concentration of Erlotinib can be decreased when it is combined with Tamoxifen. Tamsulosin The metabolism of Erlotinib can be decreased when combined with Tamsulosin. Tasimelteon The metabolism of Erlotinib can be decreased when combined with Tasimelteon. Tazarotene The metabolism of Erlotinib can be decreased when combined with Tazarotene. Tazemetostat The metabolism of Erlotinib can be decreased when combined with Tazemetostat. Tecovirimat The serum concentration of Erlotinib can be decreased when it is combined with Tecovirimat. Tegafur The metabolism of Tegafur can be decreased when combined with Erlotinib. Tegaserod The metabolism of Erlotinib can be decreased when combined with Tegaserod. Telaprevir The metabolism of Erlotinib can be decreased when combined with Telaprevir. Telavancin The risk or severity of QTc prolongation can be increased when Telavancin is combined with Erlotinib. Telithromycin The metabolism of Erlotinib can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Erlotinib can be decreased when it is combined with Telotristat ethyl. Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Erlotinib. Teniposide The metabolism of Erlotinib can be decreased when combined with Teniposide. Tenofovir alafenamide The serum concentration of Tenofovir alafenamide can be increased when it is combined with Erlotinib. Terbinafine The serum concentration of Erlotinib can be decreased when it is combined with Terbinafine. Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Erlotinib. Terfenadine The metabolism of Erlotinib can be decreased when combined with Terfenadine. Teriflunomide The serum concentration of Erlotinib can be decreased when it is combined with Teriflunomide. Teriparatide The therapeutic efficacy of Teriparatide can be decreased when used in combination with Erlotinib. Terlipressin The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Erlotinib. Testosterone The serum concentration of Erlotinib can be decreased when it is combined with Testosterone. Tetrabenazine The metabolism of Erlotinib can be decreased when combined with Tetrabenazine. Tetracaine The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Tetracaine. Tetracycline The metabolism of Erlotinib can be decreased when combined with Tetracycline. Tezacaftor The metabolism of Erlotinib can be decreased when combined with Tezacaftor. Thalidomide The metabolism of Erlotinib can be increased when combined with Thalidomide. Theophylline The metabolism of Theophylline can be decreased when combined with Erlotinib. Thiabendazole The metabolism of Erlotinib can be decreased when combined with Thiabendazole. Thiamylal The metabolism of Erlotinib can be increased when combined with Thiamylal. Thiopental The serum concentration of Erlotinib can be decreased when it is combined with Thiopental. Thioridazine The metabolism of Erlotinib can be decreased when combined with Thioridazine. Thiotepa The metabolism of Thiotepa can be decreased when combined with Erlotinib. Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Erlotinib. Thyroid, porcine The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Erlotinib. Thyrotropin alfa The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Erlotinib. Tiagabine The metabolism of Tiagabine can be decreased when combined with Erlotinib. Ticagrelor The metabolism of Erlotinib can be decreased when combined with Ticagrelor. Ticlopidine The metabolism of Erlotinib can be decreased when combined with Ticlopidine. Timolol The metabolism of Erlotinib can be decreased when combined with Timolol. Tiotropium The metabolism of Erlotinib can be decreased when combined with Tiotropium. Tipranavir The metabolism of Erlotinib can be decreased when combined with Tipranavir. Tizanidine The metabolism of Tizanidine can be decreased when combined with Erlotinib. Tocainide The metabolism of Erlotinib can be decreased when combined with Tocainide. Tocilizumab The serum concentration of Erlotinib can be decreased when it is combined with Tocilizumab. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Erlotinib. Tolbutamide The metabolism of Erlotinib can be decreased when combined with Tolbutamide. Tolterodine The metabolism of Erlotinib can be decreased when combined with Tolterodine. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Erlotinib. Topiramate The metabolism of Erlotinib can be increased when combined with Topiramate. Topotecan Erlotinib may decrease the excretion rate of Topotecan which could result in a higher serum level. Torasemide The metabolism of Erlotinib can be decreased when combined with Torasemide. Toremifene The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Toremifene. Trabectedin The metabolism of Trabectedin can be decreased when combined with Erlotinib. Tramadol The metabolism of Tramadol can be decreased when combined with Erlotinib. Trametinib The serum concentration of Erlotinib can be decreased when it is combined with Trametinib. Tranylcypromine The metabolism of Erlotinib can be decreased when combined with Tranylcypromine. Trastuzumab The metabolism of Trastuzumab emtansine can be decreased when combined with Erlotinib. Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Erlotinib. Treprostinil The serum concentration of Treprostinil can be increased when it is combined with Erlotinib. Tretinoin The metabolism of Erlotinib can be decreased when combined with Tretinoin. Triamcinolone The serum concentration of Erlotinib can be decreased when it is combined with Triamcinolone. Triamterene The metabolism of Erlotinib can be decreased when combined with Triamterene. Triazolam The metabolism of Erlotinib can be decreased when combined with Triazolam. Triclabendazole The metabolism of Erlotinib can be decreased when combined with Triclabendazole. Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Erlotinib. Trilaciclib The metabolism of Erlotinib can be increased when combined with Trilaciclib. Trimebutine The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Erlotinib. Trimethadione The metabolism of Erlotinib can be decreased when combined with Trimethadione. Trimethoprim The metabolism of Erlotinib can be decreased when combined with Trimethoprim. Trimipramine The metabolism of Trimipramine can be decreased when combined with Erlotinib. Tripelennamine The metabolism of Erlotinib can be decreased when combined with Tripelennamine. Triprolidine The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Erlotinib. Triptorelin The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Erlotinib. Troglitazone The serum concentration of Erlotinib can be decreased when it is combined with Troglitazone. Troleandomycin The metabolism of Erlotinib can be decreased when combined with Troleandomycin. Trospium The metabolism of Erlotinib can be decreased when combined with Trospium. Trovafloxacin The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Trovafloxacin. Tucatinib The metabolism of Tucatinib can be decreased when combined with Erlotinib. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Erlotinib. Udenafil The metabolism of Erlotinib can be decreased when combined with Udenafil. Umeclidinium The metabolism of Erlotinib can be decreased when combined with Umeclidinium. Valbenazine The metabolism of Erlotinib can be decreased when combined with Valbenazine. Valproic acid The metabolism of Erlotinib can be decreased when combined with Valproic acid. Vandetanib The metabolism of Vandetanib can be decreased when combined with Erlotinib. Vardenafil The metabolism of Vardenafil can be decreased when combined with Erlotinib. Velpatasvir The metabolism of Erlotinib can be decreased when combined with Velpatasvir. Vemurafenib The serum concentration of Erlotinib can be decreased when it is combined with Vemurafenib. Venetoclax The metabolism of Erlotinib can be decreased when combined with Venetoclax. Venlafaxine The metabolism of Erlotinib can be decreased when combined with Venlafaxine. Verapamil The metabolism of Erlotinib can be decreased when combined with Verapamil. Vernakalant The metabolism of Erlotinib can be decreased when combined with Vernakalant. Vilanterol The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Erlotinib. Vilazodone The metabolism of Erlotinib can be decreased when combined with Vilazodone. Viloxazine The metabolism of Erlotinib can be decreased when combined with Viloxazine. Vinblastine The serum concentration of Erlotinib can be decreased when it is combined with Vinblastine. Vincristine The metabolism of Vincristine can be decreased when combined with Erlotinib. Vindesine The metabolism of Vindesine can be decreased when combined with Erlotinib. Vinflunine The metabolism of Vinflunine can be decreased when combined with Erlotinib. Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Erlotinib. Vitamin E The serum concentration of Erlotinib can be decreased when it is combined with Vitamin E. Vonoprazan Vonoprazan can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Vorapaxar The metabolism of Erlotinib can be decreased when combined with Vorapaxar. Voriconazole The metabolism of Erlotinib can be decreased when combined with Voriconazole. Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Erlotinib. Vortioxetine The metabolism of Erlotinib can be decreased when combined with Vortioxetine. Voxelotor The serum concentration of Erlotinib can be increased when it is combined with Voxelotor. Voxilaprevir The metabolism of Erlotinib can be decreased when combined with Voxilaprevir. Warfarin The serum concentration of Warfarin can be increased when it is combined with Erlotinib. Yohimbine The metabolism of Erlotinib can be decreased when combined with Yohimbine. Zafirlukast The metabolism of Erlotinib can be decreased when combined with Zafirlukast. Zaleplon The metabolism of Erlotinib can be decreased when combined with Zaleplon. Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Erlotinib. Zidovudine The metabolism of Erlotinib can be decreased when combined with Zidovudine. Zileuton The metabolism of Erlotinib can be decreased when combined with Zileuton. Zimelidine The metabolism of Erlotinib can be decreased when combined with Zimelidine. Ziprasidone The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Ziprasidone. Zolmitriptan The metabolism of Erlotinib can be decreased when combined with Zolmitriptan. Zolpidem The metabolism of Erlotinib can be decreased when combined with Zolpidem. Zonisamide The metabolism of Erlotinib can be decreased when combined with Zonisamide. Pregnancy and Lactation FDA Pregnancy Category D  Pregnancy Erlotinib can cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised not to become pregnant while being treated with erlotinib. Erlotinib has been shown to cause maternal toxicity with associated embryofetal lethality and abortion in rabbits when given at doses that result in plasma drug concentrations of approximately 3 times those in humans (AUCs at 150 mg daily dose). When given during the period of organogenesis to achieve plasma drug concentrations approximately equal to those in humans, based on AUC, there was no increased incidence of embryofetal lethality or abortion in rabbits or rats. Lactation No information is available on the clinical use of erlotinib during breastfeeding. Because erlotinib is 93% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 36 hours and it might accumulate in the infant. It is also given in combination with gemcitabine for pancreatic cancer, which may increase the risk to the infant. The manufacturer recommends that breastfeeding be discontinued during erlotinib therapy and for 2 weeks after the final dose. How should this medicine be used?

Erlotinib comes as a tablet to take by mouth. It is usually taken on an empty stomach once a day, at least 1 hour before or 2 hours after eating a meal or snack. Take erlotinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take erlotinib exactly as directed. Do not take more or less of it or take…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   Vasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    Cholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    Imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    A thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    Propylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    Methimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    Mirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)